I have been on both sides of a denial letter. As a physician, I have told a patient their insurer said no — and not been able to tell them why. As an executive, I have sat in the room where that "no" got written, and watched how often it came down to a boilerplate policy code rather than an actual clinical judgment. That gap — between a denial and a reason — is the single biggest trust problem in health insurance, in every market I've worked in, not just wealthy ones. This year, one of the world's largest insurance systems finally started closing it, and it's worth understanding not as foreign regulatory news, but as a preview of where every claims market is headed.
What changed, and where
In the United States, a new interoperability and prior authorization rule (CMS-0057-F) became operationally binding on January 1, 2026, for Medicare Advantage organizations, Medicaid and CHIP managed care plans, and Qualified Health Plan issuers on the federal exchanges. I'm using it here as the clearest working example of a shift happening more broadly — the same pressure toward transparency is building in Europe, in parts of Asia, and in any market where claims volumes are outgrowing the trust placed in insurers to adjudicate them fairly. Here's what the US rule actually requires, concretely:
The part I think matters most isn't the clock — it's the requirement sitting next to it. Payers covered by the rule must now give a specific, clinical reason for every denial, not a reference to an internal policy number. The actual criteria that weren't met. And starting this year, plans have to publish their approval rates, denial rates, and processing times for anyone to see.
For the first time, a denial letter has to explain itself.
Even where the rule stops, the pressure doesn't
It's worth being precise about what this particular rule does not cover — traditional Medicare, employer-sponsored commercial plans, and self-funded plans are carved out in the US version. No single rule, anywhere, closes the whole gap in one pass. But that's the pattern worth watching, not the exception that disproves it: regulation starts where public pressure and political will are strongest, then spreads. A market that hasn't faced this pressure yet isn't exempt from it — it's just earlier in the timeline.
The part regulations never fix by themselves — in any market
I've run claims operations. I know the distance between "the rule requires X" and "our system actually does X" can be measured in quarters, not days — and that gap exists whether you're operating under a binding US regulation or simply trying to run an honest claims desk in a market with no such rule at all. A fast decision timeframe is only real if the utilization management queue is staffed to hit it. A "specific clinical reason" is only real if someone rewrote the denial-letter templates instead of relabeling the same boilerplate under a new field name.
That's the honest question for anyone running claims, utilization management, or revenue cycle operations right now, anywhere in the world — not "are we compliant with some foreign rule" but:
- Do our denial letters name the actual clinical criteria that weren't met, or do they still point to a policy number or a generic exclusion clause?
- Do we actually know our own average turnaround time on urgent and standard claims, under real volume — or are we guessing?
- If our approval and denial rates were published tomorrow, would they read as a plan that treats patients fairly, or one that's been getting away with something?
Where I'd put my attention next
If you lead a payer's or TPA's utilization management function — anywhere — now is the moment to audit your own denial language against this higher bar: specific clinical criteria, not policy shorthand, before a regulator, a journalist, or an angry patient's social media post does it for you. If you lead a hospital or provider organization, this is the year to start tracking payer-by-payer turnaround times yourself, because sooner or later you'll have real public data elsewhere in the world to benchmark against, instead of just anecdote.
Rules create obligations. They don't create behavior change on day one, and in markets without the rule yet, nothing forces the change at all except an insurer's own discipline. The institutions that treat transparency as a strategic choice, made before anyone compels it, are the ones that will still be trusted when the pressure eventually arrives on their doorstep too.